Oral Session 1-13A Conditioning Regimens (1)

[OS1-13A-2] Impact of different doses of fludarabine in FluBu and FluMEL regimens for uBMT

Kodai Kuriyama¹, Shigeo Fuji², Megumi Akiyama³, Koji Iwato⁴, Souichi Shiratori⁵, Yukiyasu Ozawa⁶, Takashi Ashida⁷, Junya Kanda⁸, Takahiro Fukuda⁹, Yoshiko Atsuta¹⁰, Masao Ogata¹¹ (1.Hematol, Japanese Red Cross Kyoto Daiichi Hospital, Kyoto, Japan, 2.Hematol., Osaka International Cancer Institute, Osaka, Japan, 3.Hematol., Tokyo Metropolitan Cancer and Infectious Diseases Center, Tokyo, Japan, 4.Hematol., Hiroshima Red Cross Hospital & Atomic-bomb Survivors Hospital, Hiroshima, Japan, 5.Hematol., Hokkaido University Hospital, Sapporo, Japan, 6.Hematol., Japanese Red Cross Nagoya First Hospital, Nagoya, Japan, 7.Hematol and Rheumatol., Kindai University Faculty of Medicine, Osaka, Japan, 8.Hematol and Oncol., Kyoto University, Kyoto, Japan, 9.Hematopoietic Stem Cell Transplantation Division, NCCH, Tokyo, Japan, 10.Japanese Data Center for Hematopoietic Cell Transplantation, Nagoya, Japan, 11.Hematol., Oita Univ Hospital, Oita, Japan)